Lumivatamig is a bispecific antibody designed to target CLDN18.2 and CD3E, facilitating T-cell-mediated cytotoxicity against CLDN18.2-expressing tumors. This dimer-type H-γ1_L-κ-scFvhl antibody is employed in cancer immunotherapy research to enhance anti-tumor immune responses. Its ability to bridge tumor cells and T cells may contribute to improved therapeutic outcomes in clinical applications targeting gastric and pancreatic cancers.
Lumivatamig is a bispecific antibody designed to target CLDN18.2 and CD3E, facilitating T-cell-mediated cytotoxicity against CLDN18.2-expressing tumors. This dimer-type H-γ1_L-κ-scFvhl antibody is employed in cancer immunotherapy research to enhance anti-tumor immune responses. Its ability to bridge tumor cells and T cells may contribute to improved therapeutic outcomes in clinical applications targeting gastric and pancreatic cancers.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
